DarioHealth (DRIO) Expected to Announce Earnings on Wednesday

DarioHealth (NASDAQ:DRIO) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect DarioHealth to post earnings of ($1.48) per share and revenue of $5.4560 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

DarioHealth Stock Performance

NASDAQ:DRIO opened at $8.00 on Tuesday. The company has a current ratio of 3.76, a quick ratio of 3.30 and a debt-to-equity ratio of 0.45. DarioHealth has a 12-month low of $5.93 and a 12-month high of $17.74. The stock has a 50-day moving average price of $8.18 and a 200 day moving average price of $10.67. The stock has a market capitalization of $58.40 million, a P/E ratio of -0.77 and a beta of 1.09.

Wall Street Analyst Weigh In

Several analysts recently issued reports on DRIO shares. Stifel Nicolaus cut their target price on DarioHealth from $16.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, March 20th. Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a research report on Sunday, January 25th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $35.00.

Hedge Funds Weigh In On DarioHealth

Several institutional investors have recently added to or reduced their stakes in DRIO. Kestra Advisory Services LLC purchased a new position in DarioHealth during the 4th quarter valued at approximately $35,000. XTX Topco Ltd grew its holdings in DarioHealth by 229.0% during the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after buying an additional 43,513 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after buying an additional 31,063 shares in the last quarter. Hedge funds and other institutional investors own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.